As a patient in the Center for Hematologic Oncology, you will be treated by a dedicated team committed to delivering safe, high-quality patient care. Our specialists will work with you to create a treatment plan tailored to your type of cancer and your lifestyle, to achieve the best possible outcome.
The Center for Hematologic Oncology provides specialized care for all types of cancers of the blood, including leukemia, lymphoma, multiple myeloma and Waldenström's macroglobulinemia, as well as related disorders of the blood, such as aplastic anemia and myelodysplasia.
The center also includes the bone marrow/stem cell transplantation program, which is one of the largest and most experienced in the world.
We develop personalized, comprehensive treatment plans for all our patients, offering the latest therapies and supportive resources, and taking your particular needs into account.
The Adult Leukemia Program provides care for patients with leukemia and related bone marrow disorders, including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and related bone marrow disorders, such as myelodysplasia and myelofibrosis.
The Adult Lymphoma Program provides care for the many varieties of lymphoid malignancies, including Non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, B-cell neoplasms, and T-cell neoplasms.
The Chronic Lymphocytic Leukemia Program provides care for patients with with chronic lymphocytic leukemia (CLL), and offers access to clinical trials of promising new therapies.
The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics provide care to patients with multiple myeloma, including promising new herapies through clinical trials.
The Bing Center for Waldenström's Macroglobulinemia provides care and new therapies through clinical trials to patients with Waldenström's macroglobulinemia and related Immunoglobulin M (IgM) disorders.
The center's Bone Marrow/Stem Cell Transplantation Program was one of the first in the world and is now one of the largest and busiest in the United States. Since its inception in the 1970s, our hematopoietic stem cell transplant specialists have performed more than 7,100 transplants for the treatment of blood cancers and related blood disorders.
The OHM Program is a research and clinical service that addresses the specialized needs of blood cancer patients who are age 75 and older.
Other hematologic malignancies we treat include:
To make sure your care is as seamless as possible, a dedicated team of clinicians, who are highly specialized experts in your type of blood cancer, will care for you throughout the treatment process, from diagnosis though long-term follow-up.
As a patient in the Center for Hematologic Oncology, you will be treated by a dedicated care team that includes oncologists, surgeons, hematologists, physician assistants, nurses and clinical social workers who are committed to delivering high-quality, safe, patient care.
We provide comprehensive services for treatment, including imaging, pathology, and radiation oncology. We also communicate with your referring physician throughout your treatment, including collaboration for follow-up care closer to your home where available.
In addition to conventional treatment approaches, you may have the opportunity to participate in clinical trials that offer access to new, innovative treatments for your type of cancer.
Our clinicians are actively involved in clinical research, working closely with laboratory investigators to examine a variety of treatment strategies, including:
We recognize that you and your family face many decisions and life changes. To assist you and help you make informed choices, we offer support services and education programs, resource centers and libraries, financial counseling, and low-cost, short-and long-term housing.
A variety of services and programs also support your care, including:
One distinguishing area of expertise is in our treatment of older adults (over 60 years old). Older adults with cancers of the blood often have different needs from younger adults, for example, a higher risk for heart disease, diabetes, or kidney problems, which may limit treatment options.
To address the specific needs of older patients, we offer:
Our providers work together across a range of specialty areas to coordinate fully integrated, personalized care from your initial diagnosis through long-term follow up.
Your treatment team includes physicians, physician assistants (PAs) nurse practitioners, clinical and research nurses. Laboratory investigators, clinical care coordinators, clinical social workers, and nutritionists will also be part of your care team.
Robert J. Soiffer, MDChief, Hematologic Malignancies DivisionCo-chief, Stem Cell Transplantation Program
Martha Wadleigh, MD, Clinical Director, Adult LeukemiaEric Jacobsen, MD, Clinical Director, LymphomaJacob Laubach, MD, Clinical Director, Multiple MyelomaVincent Ho, MD, Clinical Director, Stem Cell Transplantation
Janet Bagley RN, MS, AOCNS, Director of Nursing and Clinical ServicesEric Jacobsen, MD, Yawkey 8 Clinical Floor LeaderRobert Schlossman, MD, Yawkey 7 Clinical Floor LeaderDeborah Yolin Raley, PA-C, MS, Director of Physician Assistant Program
Amy Emmert, MScPH, Vice President, Hematopoietic Stem Cell Transplantation and Cell Therapies, 617-632-3876Katie Kupferberg, Manager of Disease Center Operations, 617-632-6139Amy Kazmouski, Manager of Disease Center Operations, 617-582-8355Farah Daftary, Director of Clinical Trial Operations, 617-632-2578Frantz Berthaud, Program Manager, 617-632-5073
For more information about the Hematologic Malignancies treatment center care teams, please visit the program sections:
More than 100 clinical trials are currently underway in the Center for Hematologic Oncology. The combined resources of our partner organizations within Dana-Farber/Harvard Cancer Center make us the largest cancer research center in the nation.
The leukemia team works to develop more effective, less toxic treatments for acute leukemia and related disorders, including myelodysplastic syndrome, chronic myeloid leukemia and myeloproliferative disorders.
Our clinical research focuses on understanding how leukemia cells develop and creating new ways to block their growth. We are also taking the innovative step of treating adult acute lymphoblastic leukemia (ALL) patients using treatments that have proved successful in pediatric patients.
Our lymphoma research focuses on translating laboratory findings into less toxic treatments. We are committed to investigating and understanding the genetic pathways that enable lymphoma cells to survive and manipulating them with targeted therapies to improve outcomes.
Our research program features a variety of trials specifically for chronic lymphocytic leukemia (CLL) patients, focusing on familial CLL, genomic studies and testing of novel therapies.
The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics encompasses a large team of laboratory-based and clinical scientists investigating more effective therapies for multiple myelomas. Promising new therapies are rooted in a "bench-to-bedside" approach, where laboratory discoveries are rapidly translated into the clinical setting as part of treatment.
The main goal of clinical research at the Bing Center for Waldenström's macroglobulinemia is to take laboratory discoveries to the clinic, where they can benefit patients.
Trials include studies aimed at improving outcomes of patients undergoing biological therapies that attempt to destroy the tumor cells directly; evaluating supportive therapies; and examining the genetic basis of the disease.
If you have never been seen before at Dana-Farber/Brigham and Women's Cancer Center, please call 877-442-3324, or use this online form to make an appointment. For all other inquiries, please call 617-632-5138.
Pediatric patients should call Dana-Farber/Boston Children's Cancer and Blood Disorders Center at 888-PEDI ONC (733-4662)
Contact your doctor directly, or for general inquiries, call the Hematologic Malignancies program at 617-632-6140.
Monday through Friday from 8:30 a.m.-5:00 p.m., physician offices can call 855-281-2811 to access the Hematologic Malignancies department directly. During these hours, a Hematologic Malignancies administrative team member will take your call, address your inquiry, or route it accordingly. You may also contact us via email at DFCIHemOncNewPT@partners.org.
Vice President of Hematopoietic Stem Cell Transplantation and Cell TherapiesAmy Emmert617-632-3876
Manager of Disease Center OperationsKatie Kupferberg617-632-6139
For more information about the stem cell/bone marrow donor search process, please call our Donor Services team at 866-875-DFCI (3324) or 617-632-2561.
Dana-Farber/New Hampshire Oncology-Hematology
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: